Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Recruiting · Phase 2 · NCT06350318
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $150,764
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 43
About the trial
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute (with BeOne Medicines)
- Tested
- Zanubrutinib (drug), Rituximab (drug)
- Dates
- Started 2024-04-19; completion 2029-03
- Results posted
- Not yet
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $150,764 in research payments for this study in 2025 (2 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- H. Lee Moffitt Cancer Center Foundation $150,764
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.